Net Clinical Benefit of Extended Dual Pathway Inhibition in Chronic Coronary Syndrome as Classified by the 2024 ESC Criteria: a COMPASS Substudy
{{output}}
Background and aims: Extended dual pathway inhibition (DPI) with aspirin and rivaroxaban is recommended in high-risk patients with chronic coronary syndrome (CCS). In the 2024 update of the European Society of Cardiology guidelin... ...
